About Transcode Therapeutics Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.transcodetherapeutics.com/
Frequently Asked Questions
What is the 52-week range for RNAZ?
The 52-week high is $20.99 and the 52-week low is $1.52.
What is the P/E ratio for RNAZ?
The P/E ratio data is currently unavailable.
What is the dividend yield for RNAZ?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -39.28%.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 2.52.
Analyst Recommendation Trends
Wall Street analyst consensus for RNAZ over the last few months:
Latest RNAZ News
TransCode Reports Continued Disease Stabilization and Extended Treatment Duration with TTX-MC138 in Ongoing Phase 1a Clinical Trial Follow-Up
TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA-based therapeutics for the treatment of high risk and advanced cancers, today announced updated clinical data from its Phase 1a clinical trial of TTX-MC138, its novel anti-miR-10b therapeutic candidate, in patients with relapsed or refractory, unresectable locally advanced, or metastatic solid tumors.
TransCode Therapeutics Announces Updated Clinical Data From Phase 1a Clinical Trial Of TTX-MC138, Reinforcing Evidence Of Antitumor Activity In Heavily Pretreated Patients With Advanced Solid Tumors
Updated clinical data reinforces evidence of antitumor activity in heavily pretreated patients with advanced solid tumorsIn the 14 efficacy-evaluable patients:71.4% stable disease rate57.1% of patients had disease
TransCode Therapeutics Announces Patent Advancements in Australia and Japan Strengthening Global IP Position in RNA-Based Immuno-Oncology
TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, today announced significant advancements in its global intellectual property portfolio, highlighted by (i) the acceptance of an Australian patent application and (ii) the issuance of a Notice of Allowance from the Japan Patent Office (JPO) for key technologies underpinning its RNA-based therapeutic platform.
TransCode Therapeutics Announces Australia Acceptance Of Patent application, Japan's Issuance Of Notice Of Allowance For Its RNA-Based Therapeutic Platform Technologies
TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, today announced significant advancements in its global
TransCode Therapeutics, Inc. (RNAZ) Discusses Advancing Multi-Platform Oncology Pipeline Targeting Metastatic Cancer Transcript
TransCode Therapeutics, Inc. (RNAZ) Discusses Advancing Multi-Platform Oncology Pipeline Targeting Metastatic Cancer September 16, 2026 4:15 PM EDTCompany...
Join Today's Live Investor Webinar with TransCode Therapeutics
Learn how TransCode Therapeutics is advancing RNA therapeutics, cancer vaccines, and immuno-oncology programs designed to address advanced and metastatic cancersManagement to discuss TTX-MC138, the ongoing Phase 2a colorectal cancer trial, tumor-targeted RNA delivery, and multiple upcoming clinical catalystsORLANDO, FL / ACCESS Newswire / September 16, 2026 / RedChip Companies will host an investor webinar today, September 16, 2026, at 4:15 p. ET with TransCode Therapeutics, Inc.
TransCode Therapeutics Announces Leadership Transition
TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, today announced the retirement of its Chief Financial Officer, Tom Fitzgerald. Mr. Fitzgerald has served as the Chief Financial Officer of TransCode Therapeutics since July 2018, during which time he helped lead the company through its initial public offering, the launch of its clinical program for lead product candidate, TTX-MC138, and most
TransCode Therapeutics CFO Tom Fitzgerald Plans To Retire; John Tattory To Serve As Interim Finance Chief, Effective Immediately
TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, today announced the retirement of its Chief Financial Officer,
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-09 | Fitzgerald Thomas A | +185,000 | - | - |
| 2026-08-03 | DEFJ, LLC | -202 | - | - |
| 2026-08-03 | DEFJ, LLC | -1,181 | - | - |
| 2026-08-03 | DEFJ, LLC | +2,020,582 | - | - |
| 2026-08-03 | DEFJ, LLC | +11,813,859 | - | - |